Skip to main content

PRODIGY, a Medtronic-sponsored Study: How to Assess the Risk of Respiratory Compromise

The PRODIGY study demonstrates that 41.6% of hospitalized patients receiving parenteral opioids experience respiratory compromise (RC). PRODIGY has developed a simple tool to predict which patients are at highest risk of RC, providing the first ever validated method of guiding who is best to monitor.

Click here to watch a video from study investigators on the importance of this study and click here to download more detail on the study findings.

TOPIC: Respiratory Compromise

1. Apfelbaum JL, Horlocker TT, Agarkar M, et al. Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration An Updated Report by the American Society of Anesthesiologists Task Force on Neuraxial Opioids and the American Society of Regional Anesthesia and Pain Medicine. ANESTHESIOLOGY. 2016;124(3):535-552.
2. Hinkelbein J, Lamperti M, Akeson J, Santos J, Costa J, De Robertis E, Longrois D, Novak-Jankovic V, Petrini F, Struys MMRF, Veyckemans F, Fuchs-Buder T, Fitzgerald R. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. Eur J Anaesthesiol 2017; 34:1–19

About the Author

Greg Spratt BS RRT CPFT is a respiratory therapist and former Director of Market Development at Medtronic. Greg has over 25 years’ clinical experience working with respiratory compromise across the healthcare continuum, has published articles in numerous pulmonary journals and periodicals, and presented internationally on improving solutions for patients with breath difficulties.

Profile Photo of Greg Spratt